Eli Lilly and Indiana University (IU) have announced a new agreement, under which Lilly will provide up to $40m to IU in ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Under the partnership, Lilly will pay IU up to $40 million to build clinical trial infrastructure, accelerate access to ...

Indiana University and Eli Lilly are working together to expand clinical trials in the state. IU President Pamela Whitten and ...

INDIANAPOLIS — Indiana University and pharmaceutical giant Eli Lilly have made official a five-year collaboration in which ...

Eli Lilly and Co. and Indiana University on Wednesday announced a new agreement that would see the Indianapolis-based ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Eli Lilly and Indiana University partner to expand clinical trials and innovative treatments for Hoosiers, focusing initially on Alzheimer's disease.

Indiana University and Eli Lilly and Company have signed a five-year agreement that will provide up to $40 million to expand access to clinical trials, ...

Indiana University President Pamela Whitten and Eli Lilly and Company Chair and CEO David Ricks sign the five-year agreement ...